drugset / Trial / NCT00896168

An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis

NCT00896168

Phase 4 Completed 234 enrolled Xian-Janssen Pharmaceutical Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effectiveness of iInfliximab plus methotrexate (MTX) in treatment of Rheumatoid rheumatoid Arthritis arthritis (RA) (it is an autoimmune disease that causes pain, swelling, stiffness and loss of function in joints) in participants with moderate disease versus participants with severe disease and to compare the efficacy and safety of the MTX subgroups.

Timeline

Start
2007-06
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Infliximab Monoclonal antibody 3 mg/kg Intravenous
Subject Methotrexate Small molecule 7.5 mg Oral
Subject Methotrexate Small molecule 20 mg Oral

Indications